MedPath

Ikena Oncology

Ikena Oncology logo
🇺🇸United States
Ownership
Public
Established
2016-01-01
Employees
43
Market Cap
$83.7M
Website
http://www.ikenaoncology.com
Introduction

Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

Clinical Trials

6

Active:0
Completed:2

Trial Phases

1 Phases

Phase 1:6

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (100.0%)

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Phase 1
Recruiting
Conditions
Non-Small Cell Lung Carcinoma
Gliomas, Malignant
Solid Tumor, Adult
Colorectal Cancer
Pancreatic Cancer
Malignant Melanoma
Ras (Kras or Nras) Gene Mutation
CRAF Gene Mutation
Thyroid Carcinoma
BRAF Gene Mutation
Interventions
First Posted Date
2024-02-21
Last Posted Date
2025-04-29
Lead Sponsor
Ikena Oncology
Target Recruit Count
150
Registration Number
NCT06270082
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Johns Hopkins University of Medicine Sidney Kimmel Comprehensive Care Center, Washington, District of Columbia, United States

🇺🇸

University of Miami, Miami, Florida, United States

and more 12 locations

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Phase 1
Withdrawn
Conditions
Head Cancer Neck
Neck Cancer
Head and Neck Cancer
Neck Carcinoma
Head and Neck Squamous Cell Carcinoma
Head Cancer
Interventions
First Posted Date
2022-07-25
Last Posted Date
2024-03-15
Lead Sponsor
Ikena Oncology
Registration Number
NCT05472506
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

Washington University, Saint Louis, Missouri, United States

🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 1 locations

A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2024-05-14
Last Posted Date
2024-05-23
Lead Sponsor
Ikena Oncology Inc.
Target Recruit Count
31
Registration Number
2022-502622-40-00
Locations
🇫🇷

Centre Leon Berard, Lyon, France

🇫🇷

Institut Bergonie, Bordeaux, France

🇫🇷

Centre Oscar Lambret, Lille, France

and more 3 locations

A Study of PY314 in Subjects With Advanced Solid Tumors

Phase 1
Terminated
Conditions
Advanced Solid Tumor
Triple Negative Breast Cancer
Lung Adenocarcinoma
Renal Cell Carcinoma
Ovarian Cancer
Gynecologic Cancer
Breast Cancer
Colorectal Cancer
Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer
Interventions
First Posted Date
2020-12-31
Last Posted Date
2024-03-22
Lead Sponsor
Ikena Oncology
Target Recruit Count
86
Registration Number
NCT04691375
Locations
🇺🇸

Mayo Clinic Scottsdale - PPDS, Phoenix, Arizona, United States

🇺🇸

Honor Health Research Institute, Scottsdale, Arizona, United States

🇺🇸

City of Hope - Comprehensive Cancer Center, Duarte, California, United States

and more 20 locations

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1
Terminated
Conditions
Gastric Adenocarcinoma
Colorectal Cancer
Pancreatic Cancer
Advanced Solid Tumor
Gynecologic Cancer
Breast Cancer
Lung Adenocarcinoma
Head and Neck Cancer
Interventions
Drug: PY159 Single agent dose level 4
Drug: PY159 Single agent dose level 7
Drug: PY159 Single agent dose level 2
Drug: PY159 Single agent dose level 3
Drug: PY159/Pembrolizumab Combination dose expansion cohort 6
Drug: PY159 Single agent dose level 1
Drug: PY159 Single agent dose expansion cohort
Drug: PY159/Pembrolizumab Combination dose expansion cohort 2
Drug: PY159/Pembrolizumab Combination dose expansion cohort 3
Drug: PY159 Single agent dose level 5
Drug: PY159 Single agent dose level 6
Drug: PY159/Pembrolizumab Combination dose level 3
Drug: PY159/Pembrolizumab Combination dose level 4
Drug: PY159/Pembrolizumab Combination dose expansion cohort 1
Drug: PY159/Pembrolizumab Combination dose expansion cohort 4
Drug: PY159/Pembrolizumab Combination dose expansion cohort 5
Drug: PY159/Pembrolizumab Combination dose level 1
Drug: PY159/Pembrolizumab Combination dose level 2
First Posted Date
2020-12-23
Last Posted Date
2024-03-22
Lead Sponsor
Ikena Oncology
Target Recruit Count
127
Registration Number
NCT04682431
Locations
🇺🇸

USC Norris Cancer Center, Los Angeles, California, United States

🇺🇸

UCSF Mount Zion Cancer Center, San Francisco, California, United States

🇺🇸

UCLA Parkside Cancer Center, Santa Monica, California, United States

and more 14 locations
  • Prev
  • 1
  • 2
  • Next

News

Former Poseida CEO Kristin Yarema Named to Lead Ikena-Inmagene Merger as Companies Advance Anti-OX40 Therapy

Ikena Oncology and Inmagene Biopharmaceuticals have appointed former Poseida Therapeutics CEO Kristin Yarema to lead the merged company ImageneBio following their anticipated July 2025 closing.

Hillstar Bio Strengthens Leadership Team with Key Appointments to Advance Precision Immunotherapy Pipeline

Hillstar Bio appointed Maude Tessier, Ph.D., as Chief Operating Officer and Shiva Krupa, Ph.D., MBA, as Vice President of Program Management to strengthen leadership capabilities.

Pharmaceutical Industry Faces Widespread Layoffs Amid Patent Cliffs and Economic Uncertainty

• Major pharmaceutical companies including Pfizer, Novartis, and Takeda have implemented significant workforce reductions over the past year due to patent cliffs and economic pressures. • Unlike previous trends, current layoffs are heavily impacting R&D departments, marking a shift from traditional commercial-focused cuts and reflecting the industry's evolving outsourcing landscape. • Contract Research Organizations (CROs) are benefiting from the industry shift, absorbing displaced talent and gaining additional business as pharmaceutical companies restructure their operations.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.